Continued treatment with tucatinib for people who benefited in a prior study
Treatments studied
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This study continues treatment with tucatinib for people who were already benefiting from it in a previous study. It checks if they are still eligible and willing to keep taking the drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Currently receiving tucatinib in a parent study and benefiting without disease progression
- Agree to follow reproductive criteria
- Willing and able to comply with schedule and procedures
- Capable of giving informed consent
- No medical reason precluding participation per investigator
- Not currently using prohibited medications
- Previously enrolled in parent study, not discontinued, not in control arm
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RO7771950, against another drug called tucatinib. Both are given with standard chemotherapy to see which works better for advanced breast cancer that is HER2-positive. People with brain metastases may join.
This Phase 2 trial studies tucatinib combined with oral etoposide and trastuzumab in people with metastatic HER2-positive breast cancer, aiming to slow cancer growth. You may be eligible if you previously had progression on a similar HER2-targeted treatment or cannot take capecitabine for medical reasons.
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial allows people with blood cancers who are already benefiting from tafasitamab treatment in another study to keep receiving it. It helps ensure you can continue this therapy without interruption.
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.